Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents

Rajeev K Seth, Sarwat Salim, M. Bruce Shields, Ron A. Adelman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To assess whether the transient intraocular pressure rise, frequent intraocular pressure fluctuations, or antivascular endothelial growth factor (VEGF) effects of repeated intravitreal injection of anti-VEGF agents can lead to changes in the optic nerve vertical cup-to-disk ratio (C/D). Methods: Patients with a known history of glaucoma and those receiving triamcinolone acetonide were excluded from the study. Fundus photographs were cropped to optic disk images only, which were then randomized and independently graded by two glaucoma specialists. In patients who received treatments in only one eye, the fellow eye was used as a control. Results: Twenty-three eyes of 21 patients met inclusion criteria. The mean change in C/D was -0.012 (95% confidence interval [CI], -0.053 to 0.029) for the treated group and -0.006 (95% CI, -0.106 to 0.095) for the control group, with no statistically significant difference (P = 0.90). The mean change in C/D for eyes receiving ≤5 injections (n = 9) was 0.003 (95% CI, -0.089 to 0.095) in the treated group and 0.054 (95% CI, -0.033 to 0.142) in the control group, with no statistically significant difference (P = 0.33). In eyes receiving >5 injections (n = 14), the mean change in C/D was -0.021 (95% CI, -0.095 to 0.052) in the treated group and -0.057 (95% CI, -0.231 to 0.116) in the control group, with no statistically significant difference (P = 0.70). Conclusion: There was no statistically significant change in the vertical C/D of optic nerves in patients receiving multiple intravitreal injections of anti-VEGF agents, regardless of whether they received fewer or more than five total injections. This suggests that the short-term intraocular pressure rise and frequent intraocular pressure fluctuation, as well as the anti-VEGF properties of these drugs, do not adversely change the optic nerve C/D. Additional prospective studies are warranted to confirm these conclusions.

Original languageEnglish (US)
Pages (from-to)956-959
Number of pages4
JournalRetina
Volume29
Issue number7
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Endothelial Growth Factors
Intravitreal Injections
Optic Nerve
Confidence Intervals
Intraocular Pressure
Vascular Endothelial Growth Factor A
Glaucoma
Control Groups
Injections
Triamcinolone Acetonide
Optic Disk
Prospective Studies
Pharmaceutical Preparations

Keywords

  • Intraocular pressure
  • Intravitreal injection
  • Optic nerve
  • Optic neuropathy
  • Pegaptanib sodium
  • Ranibizumab
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. / Seth, Rajeev K; Salim, Sarwat; Shields, M. Bruce; Adelman, Ron A.

In: Retina, Vol. 29, No. 7, 07.2009, p. 956-959.

Research output: Contribution to journalArticle

@article{7ccbf4203c39440195b8929a3f3b6bfe,
title = "Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents",
abstract = "Purpose: To assess whether the transient intraocular pressure rise, frequent intraocular pressure fluctuations, or antivascular endothelial growth factor (VEGF) effects of repeated intravitreal injection of anti-VEGF agents can lead to changes in the optic nerve vertical cup-to-disk ratio (C/D). Methods: Patients with a known history of glaucoma and those receiving triamcinolone acetonide were excluded from the study. Fundus photographs were cropped to optic disk images only, which were then randomized and independently graded by two glaucoma specialists. In patients who received treatments in only one eye, the fellow eye was used as a control. Results: Twenty-three eyes of 21 patients met inclusion criteria. The mean change in C/D was -0.012 (95{\%} confidence interval [CI], -0.053 to 0.029) for the treated group and -0.006 (95{\%} CI, -0.106 to 0.095) for the control group, with no statistically significant difference (P = 0.90). The mean change in C/D for eyes receiving ≤5 injections (n = 9) was 0.003 (95{\%} CI, -0.089 to 0.095) in the treated group and 0.054 (95{\%} CI, -0.033 to 0.142) in the control group, with no statistically significant difference (P = 0.33). In eyes receiving >5 injections (n = 14), the mean change in C/D was -0.021 (95{\%} CI, -0.095 to 0.052) in the treated group and -0.057 (95{\%} CI, -0.231 to 0.116) in the control group, with no statistically significant difference (P = 0.70). Conclusion: There was no statistically significant change in the vertical C/D of optic nerves in patients receiving multiple intravitreal injections of anti-VEGF agents, regardless of whether they received fewer or more than five total injections. This suggests that the short-term intraocular pressure rise and frequent intraocular pressure fluctuation, as well as the anti-VEGF properties of these drugs, do not adversely change the optic nerve C/D. Additional prospective studies are warranted to confirm these conclusions.",
keywords = "Intraocular pressure, Intravitreal injection, Optic nerve, Optic neuropathy, Pegaptanib sodium, Ranibizumab, Vascular endothelial growth factor",
author = "Seth, {Rajeev K} and Sarwat Salim and Shields, {M. Bruce} and Adelman, {Ron A.}",
year = "2009",
month = "7",
doi = "10.1097/IAE.0b013e3181a91dfd",
language = "English (US)",
volume = "29",
pages = "956--959",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents

AU - Seth, Rajeev K

AU - Salim, Sarwat

AU - Shields, M. Bruce

AU - Adelman, Ron A.

PY - 2009/7

Y1 - 2009/7

N2 - Purpose: To assess whether the transient intraocular pressure rise, frequent intraocular pressure fluctuations, or antivascular endothelial growth factor (VEGF) effects of repeated intravitreal injection of anti-VEGF agents can lead to changes in the optic nerve vertical cup-to-disk ratio (C/D). Methods: Patients with a known history of glaucoma and those receiving triamcinolone acetonide were excluded from the study. Fundus photographs were cropped to optic disk images only, which were then randomized and independently graded by two glaucoma specialists. In patients who received treatments in only one eye, the fellow eye was used as a control. Results: Twenty-three eyes of 21 patients met inclusion criteria. The mean change in C/D was -0.012 (95% confidence interval [CI], -0.053 to 0.029) for the treated group and -0.006 (95% CI, -0.106 to 0.095) for the control group, with no statistically significant difference (P = 0.90). The mean change in C/D for eyes receiving ≤5 injections (n = 9) was 0.003 (95% CI, -0.089 to 0.095) in the treated group and 0.054 (95% CI, -0.033 to 0.142) in the control group, with no statistically significant difference (P = 0.33). In eyes receiving >5 injections (n = 14), the mean change in C/D was -0.021 (95% CI, -0.095 to 0.052) in the treated group and -0.057 (95% CI, -0.231 to 0.116) in the control group, with no statistically significant difference (P = 0.70). Conclusion: There was no statistically significant change in the vertical C/D of optic nerves in patients receiving multiple intravitreal injections of anti-VEGF agents, regardless of whether they received fewer or more than five total injections. This suggests that the short-term intraocular pressure rise and frequent intraocular pressure fluctuation, as well as the anti-VEGF properties of these drugs, do not adversely change the optic nerve C/D. Additional prospective studies are warranted to confirm these conclusions.

AB - Purpose: To assess whether the transient intraocular pressure rise, frequent intraocular pressure fluctuations, or antivascular endothelial growth factor (VEGF) effects of repeated intravitreal injection of anti-VEGF agents can lead to changes in the optic nerve vertical cup-to-disk ratio (C/D). Methods: Patients with a known history of glaucoma and those receiving triamcinolone acetonide were excluded from the study. Fundus photographs were cropped to optic disk images only, which were then randomized and independently graded by two glaucoma specialists. In patients who received treatments in only one eye, the fellow eye was used as a control. Results: Twenty-three eyes of 21 patients met inclusion criteria. The mean change in C/D was -0.012 (95% confidence interval [CI], -0.053 to 0.029) for the treated group and -0.006 (95% CI, -0.106 to 0.095) for the control group, with no statistically significant difference (P = 0.90). The mean change in C/D for eyes receiving ≤5 injections (n = 9) was 0.003 (95% CI, -0.089 to 0.095) in the treated group and 0.054 (95% CI, -0.033 to 0.142) in the control group, with no statistically significant difference (P = 0.33). In eyes receiving >5 injections (n = 14), the mean change in C/D was -0.021 (95% CI, -0.095 to 0.052) in the treated group and -0.057 (95% CI, -0.231 to 0.116) in the control group, with no statistically significant difference (P = 0.70). Conclusion: There was no statistically significant change in the vertical C/D of optic nerves in patients receiving multiple intravitreal injections of anti-VEGF agents, regardless of whether they received fewer or more than five total injections. This suggests that the short-term intraocular pressure rise and frequent intraocular pressure fluctuation, as well as the anti-VEGF properties of these drugs, do not adversely change the optic nerve C/D. Additional prospective studies are warranted to confirm these conclusions.

KW - Intraocular pressure

KW - Intravitreal injection

KW - Optic nerve

KW - Optic neuropathy

KW - Pegaptanib sodium

KW - Ranibizumab

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=68249090015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249090015&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181a91dfd

DO - 10.1097/IAE.0b013e3181a91dfd

M3 - Article

VL - 29

SP - 956

EP - 959

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -